Stockreport

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024 [Yahoo! Finance]

Q32 Bio Inc.  (QTTB) 
PDF ascending dose clinical trial of ADX-097 in healthy volunteers; results support Phase 2 dose selection and continued clinical advancement of ADX-097 -- WALTHAM, Mass. [Read more]